Assmann G, Schulte H: The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J. 1988, 116: 1713-24. 10.1016/0002-8703(88)90220-7
Article
CAS
PubMed
Google Scholar
Ishikawa M, Namiki A, Kubota T, Yajima S, Fukazawa M, Moroi M: Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia. Intern Med. 2006, 45: 51-5. 10.2169/internalmedicine.45.1476
Article
PubMed
Google Scholar
Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK: Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol. 2010, 55: 1209-16. 10.1016/j.jacc.2009.10.053
Article
PubMed Central
CAS
PubMed
Google Scholar
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359: 2195-207. 10.1056/NEJMoa0807646
Article
CAS
PubMed
Google Scholar
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010, 375: 735-42. 10.1016/S0140-6736(09)61965-6
Article
CAS
PubMed
Google Scholar
Zaharan NL, Williams D, Bennett K: Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol. 2013, 75: 1118-24. 10.1111/j.1365-2125.2012.04403.x
Article
PubMed Central
CAS
PubMed
Google Scholar
Lim S, Oh PC, Sakuma I, Koh KK: How to balance cardiorenometabolic benefits and risks of statins. Atherosclerosis. 2014, 235: 644-8. 10.1016/j.atherosclerosis.2014.06.001
Article
CAS
PubMed
Google Scholar
Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011, 305: 2556-64. 10.1001/jama.2011.860
Article
CAS
PubMed
Google Scholar
Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP: The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005, 102: 8132-7. 10.1073/pnas.0500269102
Article
PubMed Central
CAS
PubMed
Google Scholar
Hawes BE, O’Neill KA, Yao X, Crona JH, Davis HR, Graziano MP: In vivo responsiveness to ezetimibe correlates with niemann-pick C1 like-1 (NPC1L1) binding affinity: Comparison of multiple species NPC1L1 orthologs. Mol Pharmacol. 2007, 71: 19-29. 10.1124/mol.106.027896
Article
CAS
PubMed
Google Scholar
Dagli N, Yavuzkir M, Karaca I: The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation. 2007, 30: 230-5. 10.1007/s10753-007-9041-3
Article
CAS
PubMed
Google Scholar
Tamaki N, Ueno H, Morinaga Y, Shiiya T, Nakazato M: Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. J Atheroscler Thromb. 2012, 19: 532-8. 10.5551/jat.10835
Article
CAS
PubMed
Google Scholar
Yagi S, Akaike M, Aihara K, Iwase T, Ishikawa K, Yoshida S: Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J Atheroscler Thromb. 2010, 17: 173-80. 10.5551/jat.2378
Article
CAS
PubMed
Google Scholar
Gonzalez-Ortiz M, Martinez-Abundis E, Kam-Ramos AM, Hernandez-Salazar E, Ramos-Zavala MG: Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Cardiovasc Drugs Ther. 2006, 20: 143-6. 10.1007/s10557-006-7805-x
Article
CAS
PubMed
Google Scholar
Kikuchi K, Nezu U, Inazumi K, Miyazaki T, Ono K, Orime K: Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J Atheroscler Thromb. 2012, 19: 1093-101. 10.5551/jat.12427
Article
CAS
PubMed
Google Scholar
Kishimoto M, Sugiyama T, Osame K, Takarabe D, Okamoto M, Noda M: Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes. J Med Invest. 2011, 58: 86-94. 10.2152/jmi.58.86
Article
PubMed
Google Scholar
Toth PP, Catapano A, Farnier M, Foody J, Tomassini JE, Jensen E: Changes in Fasting Glucose Levels Following Longer-term Treatment with Simvastatin Monotherapy and Combined Ezetimibe + Simvastatin [abstract]. JACC. 2014, 63: A1313-10.1016/S0735-1097(14)61313-9.
Article
Google Scholar
Toth PP, Catapano A, Farnier M, Foody J, Tomassini JE, Jensen E: Effects of Ezetimibe, Ezetimibe Coadministered with Statins and Statin Therapies on Fasting Glucose Changes in Patients with Hypercholesterolemia [abstract]. J Clin Lipidol. 2013, 7: 277-10.1016/j.jacl.2013.03.082.
Article
Google Scholar
Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM: Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009, 32: 1924-9. 10.2337/dc09-0738
Article
PubMed Central
CAS
PubMed
Google Scholar
Robinson JG, Ballantyne CM, Grundy SM, Hsueh WA, Parving HH, Rosen JB: Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol. 2009, 103: 1694-702. 10.1016/j.amjcard.2009.05.003
Article
CAS
PubMed
Google Scholar
Uemura Y, Watarai M, Ishii H, Koyasu M, Takemoto K, Yoshikawa D: Atorvastatin 10 mg plus ezetimibe 10 mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol. 2012, 59: 50-6. 10.1016/j.jjcc.2011.09.001
Article
PubMed
Google Scholar
Labonte ED, Camarota LM, Rojas JC, Jandacek RJ, Gilham DE, Davies JP: Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1−/− mice. Am J Physiol Gastrointest Liver Physiol. 2008, 295: G776-83. 10.1152/ajpgi.90275.2008
Article
PubMed Central
CAS
PubMed
Google Scholar
Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M: Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 2007, 581: 5664-70. 10.1016/j.febslet.2007.11.023
Article
CAS
PubMed
Google Scholar
Zhong Y, Wang J, Gu P, Shao J, Lu B, Jiang S: Effect of ezetimibe on insulin secretion in db/db diabetic mice. Exp Diabetes Res. 2012, 2012: 420854-
PubMed Central
PubMed
Google Scholar
Tsunoda T, Nozue T, Yamada M, Mizuguchi I, Sasaki M, Michishita I: Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract. 2013, 100: 46-52. 10.1016/j.diabres.2012.12.026
Article
CAS
PubMed
Google Scholar
Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003, 107: 2409-15. 10.1161/01.CIR.0000068312.21969.C8
Article
CAS
PubMed
Google Scholar
Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R: A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2004, 26: 1758-73. 10.1016/j.clinthera.2004.11.016
Article
CAS
PubMed
Google Scholar
Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002, 40: 2125-34. 10.1016/S0735-1097(02)02610-4
Article
CAS
PubMed
Google Scholar
Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002, 90: 1092-7. 10.1016/S0002-9149(02)02798-4
Article
CAS
PubMed
Google Scholar
Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB: Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004, 79: 620-9. 10.4065/79.5.620
Article
CAS
PubMed
Google Scholar
Kerzner B, Corbelli J, Sharp S, Lipka LJ, Melani L, LeBeaut A: Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol. 2003, 91: 418-24. 10.1016/S0002-9149(02)03236-8
Article
CAS
PubMed
Google Scholar
Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ: Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003, 24: 729-41. 10.1016/S0195-668X(02)00807-2
Article
CAS
PubMed
Google Scholar
Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeaut A: Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J. 2003, 24: 717-28. 10.1016/S0195-668X(02)00803-5
Article
CAS
PubMed
Google Scholar
Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A: Ezetimibe monotherapy for cholesterol lowering in 2, 722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009, 265: 568-80. 10.1111/j.1365-2796.2008.02062.x
Article
CAS
PubMed
Google Scholar
Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA: Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18, 144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014, 168: 205-12. 10.1016/j.ahj.2014.05.004
Article
CAS
PubMed
Google Scholar
Blazing MA, Guigliano R, Cannon CP, Musliner TA, Tershakovec AM, White JA: IMProved Reduction of Outcomes: Vytorin Efficacy International Trial: On-treatment analysis [abstract]. 2014
Google Scholar
Cannon CP, On behalf of the IMPROVE-IT investigators.IMProved Reduction of Outcomes: Vytorin Efficacy International Trial [abstract]. 2014.
Google Scholar